Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02656706
Title BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors howard safran



Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.